- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05213949
An Observational Study of Risk Factors and Long-term Prognosis of Patients With Liver Abscess in the "Real-world"
August 5, 2022 updated by: Nanfang Hospital of Southern Medical University
An Observational Study of Risk Factors and Long-term Prognosis of Patients With Pyogenic Liver Abscess in the "Real-world"
Pyogenic liver abscess is one of the most common visceral abscesses, its incidence is increasing worldwide.
According to the previous literature, the mortality rate of pyogenic liver abscess is as high as 31% and become a serious social health problem.
However, the data of prospective observational real-world studies are scarce and no relevant research of the liver histological change has been reported, so the long-term prognosis and the risk factors for pyogenic liver abscess are still unknown.
Patients will be followed up prospectively for a period of 2 years and observed clinical prognosis (all-cause mortality, the recurrence rate, and the rehospitalization rate).
The investigators will investigate the predictive value of clinical risk factors for clinical prognosis and establish clinical prediction models to predict the long-term prognosis of pyogenic liver abscesses.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
160
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xuyen Xu, MD
- Phone Number: 020-62786539
- Email: xuxuwen95@126.com
Study Contact Backup
- Name: Muye Xia, MD
- Phone Number: +86 17665730806
- Email: xiamuye@foxmail.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 5100515
- Recruiting
- Nanfang Hospital of Southern Medical University
-
Contact:
- Xuyen M University, MD
- Phone Number: 02062786539
- Email: xuxuwen95@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients older than 18 years of age admitted for pyogenic liver abscesses
Description
Inclusion Criteria:
- Patients older than 18 years of age;
- Irrespective of gender;
- Symptomatic patients of liver abscess confirmed with radiology imaging, either by ultrasonography or computed tomography scan.
Exclusion Criteria:
- Patients <18 years old;
- Pregnancy at presentation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion and causes of deaths within 2 years of discharge from hospital
Time Frame: 2 years
|
Define the proportion and causes of deaths within 2 years of discharge from hospital for patients admitted to the Department for pyogenic liver abscesses.
|
2 years
|
|
Proportion and causes of re-hospitalization within 2 years of discharge from hospital
Time Frame: 2 years
|
Define the proportion and causes of re-hospitalization within 2 years of discharge from hospital for patients admitted to the Department for pyogenic liver abscesses.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The recurrence rate of pyogenic liver abscess
Time Frame: 2 years
|
Development new liver abscess after clinical cure during the 2 years follow up period
|
2 years
|
|
The number of participants with Histological Change in the Liver
Time Frame: 2 years
|
Assessment of histological change in the liver by using ultrasonography or transient elastography during the 2 years follow up period
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Anticipated)
January 1, 2025
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
December 30, 2021
First Submitted That Met QC Criteria
January 17, 2022
First Posted (Actual)
January 28, 2022
Study Record Updates
Last Update Posted (Actual)
August 8, 2022
Last Update Submitted That Met QC Criteria
August 5, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NFEC-2021-355
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
There is no plan to share IPD with other researchers except for those are directly involved with this study.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
University Hospital, Strasbourg, FranceRecruiting
-
Han TongyanCompletedLower Respiratory Tract Infections | RSV InfectionsChina
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdRecruitingRespiratory Syncytial Virus InfectionsChina
-
GlaxoSmithKlineRecruiting
-
ShionogiRecruitingRespiratory Syncytial Virus InfectionsUnited States, Bulgaria, South Africa, Poland, Japan
-
Kevin WinthropAN2 Therapeutics, IncRecruitingMycobacterium Abscessus InfectionUnited States
-
Dilla UniversityNot yet recruiting
-
Emergent BioSolutionsDepartment of Health and Human Services; Centers for Disease Control and PreventionNot yet recruitingInfections, Bacterial
-
PfizerNot yet recruitingRespiratory Syncytial Virus Infections
-
Chinese University of Hong KongRecruitingTuberculosisHong Kong